Advertisement

Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches

  • Bincy P. Abraham
  • Tasneem Ahmed
  • Tauseef AliEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 239)

Abstract

Inflammatory bowel diseases, most commonly categorized as Crohn’s disease and ulcerative colitis, are immune mediated chronic inflammatory disorders of the gastrointestinal tract. The etiopathogenesis is multifactorial with different environmental, genetic, immune mediated, and gut microbial factors playing important role. The current goals of therapy are to improve clinical symptoms, control inflammation, prevent complications, and improve quality of life. Different therapeutic agents, with their indications, mechanisms of action, and side effects are discussed in this chapter. Anti-integrin therapy, a newer therapeutic class, with its potential beneficial role in both Crohn’s disease and ulcerative colitis is also mentioned. In the end, therapeutic algorithms for both diseases are reviewed.

Keywords

Adaptive immunity Anti integrins Anti-TNF drugs Biologics Corticosteroids Crohn’s disease Immunomodulators Inflammation Inflammatory bowel disease Innate immunity Mesalamine Ulcerative colitis 

References

  1. Abegunde AT, Muhammad BH, Bhatti O, Ali T (2016) Environmental risk factors for inflammatory bowel diseases: evidence based literature review. World J Gastroenterol 22(27):6296–317PubMedPubMedCentralCrossRefGoogle Scholar
  2. Abreu MT, Fukata M, Arditi M (2005) TLR signaling in the gut in health and disease. J Immunol 174:4453–4460PubMedCrossRefGoogle Scholar
  3. Akerkar GA, Peppercorn MA, Hamel MB (1997) Corticosteroid-associated complications in elderly Crohn’s disease patients. Am J Gastroenterol 92:461–464PubMedGoogle Scholar
  4. Ananthakrishnan AN, Khalili H, Higuchi LM, Bao Y, Korzenik JR, Giovannucci EL, Richter JM, Fuchs CS, Chan AT (2012) Higher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology 142:482–489PubMedCrossRefGoogle Scholar
  5. Andrews WW et al (2003) Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Obstet Gynecol 101:847–855PubMedCrossRefGoogle Scholar
  6. Armuzzi A, Gionchetti P, Daperno M, Danese S et al (2016) Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe inflammatory bowel disease. Dig Liver Dis 48:360–337PubMedCrossRefGoogle Scholar
  7. Bayer A, Gajewska A, Stephens M, Stark JM, Pathy J (1987) Pharmacokinetics of ciprofloxacin in the elderly. Respiration 51:292–295PubMedCrossRefGoogle Scholar
  8. Ben-Horin S et al (2010) Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 8:475–476PubMedCrossRefGoogle Scholar
  9. Ben-Horin S et al (2011) Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 5:555–558PubMedCrossRefGoogle Scholar
  10. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G (1995) Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 172:525–529PubMedCrossRefGoogle Scholar
  11. Cantorna MT, Zhu Y, Froicu M, Wittke A (2004) Vitamin D status,1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 80:1717S–1720SPubMedGoogle Scholar
  12. Carla-Moreau A, Paul S, Roblin X, Genin C, Peyrin-Biroulet L (2015) Prevention and treatment of postoperative Crohn’s disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials. Dig Liver Dis 47(3):191–196PubMedCrossRefGoogle Scholar
  13. Caro-Paton T et al (1997) Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 44:179–182PubMedPubMedCentralCrossRefGoogle Scholar
  14. Castiglione F, Rispo A, Di Girolamo E, Cozzolino A, Manguso F, Grassia R, Mazzacca G (2003) Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn’s disease. Aliment Pharmacol Ther 18(11–12):1107PubMedCrossRefGoogle Scholar
  15. Cho JH, Brant SR (2011) Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140:1704–1712PubMedPubMedCentralCrossRefGoogle Scholar
  16. Cobrin GM, Abreu MT (2005) Defects in mucosal immunity leading to Crohn’s disease. Immunol Rev 206:277–295PubMedCrossRefGoogle Scholar
  17. Coelho J, Beaugerie L, Colombel JF et al (2011) Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 60:198–203PubMedCrossRefGoogle Scholar
  18. Cohen RD, Woseth DM, Thisted RA, Hanauer SB (2000) A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95:1263–1276PubMedCrossRefGoogle Scholar
  19. Colombel JF, Sandborn WJ, Rutgeerts P et al (2007a) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65PubMedCrossRefGoogle Scholar
  20. Colombel JF, Sandborn WJ, Rutgeerts P et al (2007b) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65PubMedCrossRefGoogle Scholar
  21. Colombel JF, Sandborn WJ, Reinisch W et al (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362:1383–1395PubMedCrossRefGoogle Scholar
  22. Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ (2015) Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease – a SONIC post hoc analysis. Aliment Pharmacol Ther 41:734–746PubMedCrossRefGoogle Scholar
  23. Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P et al (2010) NOD2 stimu-lation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 16:90–97PubMedCrossRefGoogle Scholar
  24. Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D’Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, Danese S, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A (2011) Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 9:30–35PubMedCrossRefGoogle Scholar
  25. Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM (2015) Ulcerative colitis care pathway. Gastroenterology 149:238–245PubMedCrossRefGoogle Scholar
  26. Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, Ananthakrishnan AN (2013a) Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 19:309–315PubMedPubMedCentralCrossRefGoogle Scholar
  27. Desai A, Zator ZA, deSilva P et al (2013b) Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 19:309–315PubMedPubMedCentralCrossRefGoogle Scholar
  28. Dubinsky M, Mahadevan U, Vermeire S, Abhyankar B, Lasch K (2015) Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. P563. ECCOGoogle Scholar
  29. El MM, El-Hachem S, Harrison JR, Binion DG (2010) Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. Curr Drug Targets 11:234–241CrossRefGoogle Scholar
  30. Feagan BG, Rochon J, Fedorak RN et al (1995) Methotrexate for the treatment of Crohn’s disease. the North American Crohn’s Study Group Investigators. N Engl J Med 332:292–297PubMedCrossRefGoogle Scholar
  31. Feagan BG, Fedorak RN, Irvine EJ et al (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 342:1627–1632PubMedCrossRefGoogle Scholar
  32. Feagan BG, Rutgeerts P, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369:699–710PubMedCrossRefGoogle Scholar
  33. Feagan BG, McDonald JW, Panaccione R et al (2014a) Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology 146:681–688PubMedCrossRefGoogle Scholar
  34. Feagan BG, McDonald JWD, Panaccione R et al (2014b) Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology 146:681–688PubMedCrossRefGoogle Scholar
  35. Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK, Rutgeerts P (2007) Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 13:123–128PubMedCrossRefGoogle Scholar
  36. Ford AC, Bernstein CN, Khan KJ et al (2011) Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106:590–599PubMedCrossRefGoogle Scholar
  37. Frei P, Biedermann L, Nielsen OH, Rogler G (2013) Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 19(7):1040–1048PubMedPubMedCentralCrossRefGoogle Scholar
  38. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, Johansson R, Ferrieri A, Poggioli G, Campieri M (1999) Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 13(6):713PubMedCrossRefGoogle Scholar
  39. Greenberg GR, Feagan BG, Martin F et al (1994) Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 331:836–841PubMedCrossRefGoogle Scholar
  40. Greenwald DA, Brandt LJ (2003) Inflammatory bowel disease after age 60. Curr Treat Options Gastroenterol 6:213–225PubMedCrossRefGoogle Scholar
  41. Gudsoorkar VS, Abraham BP (2015) Inflammatory bowel disease in the elderly: hazards of generalizing the evidence. Pract Gastroenterol 39(8):26–40Google Scholar
  42. Haber CJ, Meltzer SJ, Present DH, Korelitz BI (1986) Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 91:982–986PubMedCrossRefGoogle Scholar
  43. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549PubMedCrossRefGoogle Scholar
  44. Hanauer SB, Sandborn WJ, Rutgeerts P et al (2006) Humananti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130:323–333PubMedCrossRefGoogle Scholar
  45. Hebuterne X, Lemann M, Bouhnik Y et al (2012) Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 62:201–208PubMedPubMedCentralCrossRefGoogle Scholar
  46. Hosseini-Carroll P, Mutyala M, Seth A et al (2015) Pregnancy and inflammatory bowel diseases. World J Gastrointest Pharmacol Ther 6(4):156–171PubMedPubMedCentralCrossRefGoogle Scholar
  47. Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, Present D, Farraye FA, Wolf D, Sandborn WJ (2007) Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Crohn’s and Colitis Foundation of America Clinical Alliance. Inflamm Bowel Dis 13(10):1250PubMedCrossRefGoogle Scholar
  48. Ishida K, Inoue T, Fujiwara K et al (2013) Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients. World J Gastroenterol 19:2676–2682PubMedPubMedCentralCrossRefGoogle Scholar
  49. Jarnerot G, Rolny P, Sandberg-Gertzen H (1985) Intensive intravenous treatment of ulcerative colitis. Gastroenterology 89:1005–1013PubMedCrossRefGoogle Scholar
  50. Kandiel A, Fraser AG, Korelitz BI et al (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54:1121–1125PubMedPubMedCentralCrossRefGoogle Scholar
  51. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Abadir A, Marshall JK, Talley NJ, Moayyedi P (2011) Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 106(4):661PubMedCrossRefGoogle Scholar
  52. Klebanoff MA et al (2001) Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 345:487–493PubMedCrossRefGoogle Scholar
  53. Kornbluth A, Sachar DB (2010) Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 105:501–523PubMedCrossRefGoogle Scholar
  54. Laharie D, Bourreille A, Branche J et al (2012) Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380:1909–1915PubMedCrossRefGoogle Scholar
  55. Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH (1992) Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 23:328–364PubMedCrossRefGoogle Scholar
  56. LeBel M, Barbeau G, Bergeron MG, Roy D, Vallee F (1986) Pharmacokinetics of ciprofloxacin in elderly subjects. Pharmacotherapy 6:87–91PubMedCrossRefGoogle Scholar
  57. Leman M, Mary J-Y, Duclos B et al (2006) Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 130:1054–1061CrossRefGoogle Scholar
  58. Lichtenstein GR, Abreu MT, Cohen R et al (2006) American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130:940–987PubMedCrossRefGoogle Scholar
  59. Lichtenstein GR, Hanauer SB, Sandborn WJ (2012) Risk of biologic therapy-associated progressive multifocal leukoencephalopathy: use of the JC virus antibody assay in the treatment of moderate-to-severe Crohn’s disease. Gastroenterol Hepatol 8(11 Suppl 8):1–20Google Scholar
  60. Liu JZ, Van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A et al (2015) Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 47(9):979–986PubMedPubMedCentralCrossRefGoogle Scholar
  61. Lobatón T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S (2015) Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. doi: 10.1111/apt.13294. Epub ahead of printPubMedGoogle Scholar
  62. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD (2010) Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 8:268–274PubMedPubMedCentralCrossRefGoogle Scholar
  63. Mahadevan U et al (2012) PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Updated presentation at the DDW 2012. Gastroenterology 142(Suppl 5):S149CrossRefGoogle Scholar
  64. Mahadevan U et al (2013) Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11:286–292PubMedCrossRefGoogle Scholar
  65. McKenzie SA, Selley JA, Agnew JE (1975) Secretion of prednisolone into breast milk. Arch Dis Child 50:894–896PubMedPubMedCentralCrossRefGoogle Scholar
  66. Nazareth M, Cristiano L, Kooijmans M (2008) Natalizumab use during pregnancy. Am J Gastroenterol 104:S114Google Scholar
  67. Panaccione R, Ghosh S, Middleton S et al (2014) Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146:392–400PubMedCrossRefGoogle Scholar
  68. Park-Wyllie L, Mazzotta P, Pastuszak A et al (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62(6):385–392PubMedCrossRefGoogle Scholar
  69. Peyrin-Biroulet L, Sandborn W, Sands BE et al (2015) Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110(9):1324–1338. doi: 10.1038/ajg.2015.233 PubMedCrossRefGoogle Scholar
  70. Present DH, Meltzer SJ, Krumholz MP et al (1989) 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 111:641–649PubMedCrossRefGoogle Scholar
  71. Probert CSJ, Dignass AU, Lindgren S, Pool MO, Marteau P (2014) Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis 8(3):200–207PubMedCrossRefGoogle Scholar
  72. Reenaers C, Louis E, Belaiche J et al (2012) Does co-treatment with immunosuppressors improve outcome in patients with Crohn’s disease treated with adalimumab? Aliment Pharmacol Ther 36:1040–1048PubMedCrossRefGoogle Scholar
  73. Reinisch W, Sandborn WJ, Hommes DW et al (2011) Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60:780–787PubMedCrossRefGoogle Scholar
  74. Rosenberg JL, Levin B, Wall AJ, Kirsner JB (1975) A controlled trial of azathioprine in Crohn’s disease. Am J Dig Dis 20(8):721–726PubMedCrossRefGoogle Scholar
  75. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F et al (1995) Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 108:1617–1621PubMedCrossRefGoogle Scholar
  76. Rutgeerts P, Feagan BG, Lichtenstein GR et al (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:402–413PubMedCrossRefGoogle Scholar
  77. Rutgeerts P, Sandborn WJ, Feagan BG et al (2005a) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476PubMedCrossRefGoogle Scholar
  78. Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F et al (2005b) Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128:856–861PubMedCrossRefGoogle Scholar
  79. Rutgeerts P, Van Assche G, Sandborn WJ et al (2012) Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 142:1102–1111PubMedCrossRefGoogle Scholar
  80. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G, Nichols T, Targan S, Fleishman C, Wiita B (1997) A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92(10):1867–1871PubMedGoogle Scholar
  81. Sandborn WJ, Colombel JF, Enns R, Feagan BG et al (2005) Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 353(18):1912–1925PubMedCrossRefGoogle Scholar
  82. Sandborn WJ, Rutgeerts P, Enns R et al (2007a) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146:829–838PubMedCrossRefGoogle Scholar
  83. Sandborn WJ, Feagan BG, Stoinov S et al (2007b) Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 357:228–238PubMedCrossRefGoogle Scholar
  84. Sandborn WJ, Abreu MT, D’Haens G et al (2010) Certolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 8:688–695PubMedCrossRefGoogle Scholar
  85. Sandborn WJ, van Assche G, Reinisch W et al (2012) Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142:257–265PubMedCrossRefGoogle Scholar
  86. Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction andmaintenance therapy for Crohn’s disease. N Engl J Med 369:711–721PubMedCrossRefGoogle Scholar
  87. Sandborn WJ, Feagan BG, Marano C et al (2014a) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85–95PubMedCrossRefGoogle Scholar
  88. Sandborn WJ, Feagan BG, Marano C et al (2014b) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146(1):96–109PubMedCrossRefGoogle Scholar
  89. Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885PubMedCrossRefGoogle Scholar
  90. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F (2010) Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 105:162–169PubMedCrossRefGoogle Scholar
  91. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al (2007) Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 357:239–250PubMedCrossRefGoogle Scholar
  92. Schreiber S, Lawrance IC, Thomsen O et al (2011) Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 33:185–193PubMedCrossRefGoogle Scholar
  93. Shah SC, Colombel JF, Sands BE, Narula N (2016) Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol pii: S1542-3565(16)00107-5 [Epub ahead of print]. doi:  10.1016/j.cgh.2016.01.015
  94. Shea B, Swinden MV, Ghogomu ET et al (2014) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol 41:1049–1060PubMedCrossRefGoogle Scholar
  95. Shen B, Fazio VW, Remzi FH, Bennett AE, Lopez R, Brzezinski A, Oikonomou I, Sherman KK, Lashner BA (2007) Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 50(4):498PubMedCrossRefGoogle Scholar
  96. Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA (1979) National cooperative Crohn’s disease study: adverse reactions to study drugs. Gastroenterology 77:870–882PubMedGoogle Scholar
  97. Sipponen T, Kärkkäinen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M (2008a) Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther 28:1221–1229PubMedCrossRefGoogle Scholar
  98. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M (2008b) Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 14:40–46PubMedCrossRefGoogle Scholar
  99. Soler D, Chapman T, Yang LL et al (2009) The binding specificity and selective antagonism of Vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330(3):864–875PubMedCrossRefGoogle Scholar
  100. Subramaniam K, D’Rozario J, Pavli P (2013) Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol 28:24–30PubMedCrossRefGoogle Scholar
  101. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW (1979) National cooperative Crohn’s disease study: results of drug treatment. Gastroenterology 77(4 Pt 2):847–869PubMedGoogle Scholar
  102. Targan SR, Karp LC (2005) Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 206:296–305PubMedCrossRefGoogle Scholar
  103. Targan SR, Feagan BG, Fedorak RN, Lashner BA et al (2007) Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology 132(5):1672–1683PubMedCrossRefGoogle Scholar
  104. Travis SP, Danese S, Kupcinskas L et al (2014) Once-daily budesonide MMX inactive, mild-to-moderate ulcerative colitis: results from the randomized CORE II study. Gut 63:433–441PubMedCrossRefGoogle Scholar
  105. Truelove SC, Witts LJ (1954) Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. BMJ 2:375–378PubMedPubMedCentralCrossRefGoogle Scholar
  106. Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A et al (2014) The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 147(5):990–1007PubMedPubMedCentralCrossRefGoogle Scholar
  107. van Dieren JM, Kuipers EJ, Janneke N, Samsom JN et al (2006) Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 12:311–327PubMedCrossRefGoogle Scholar
  108. Vieira A, Fang CB, Rolim EG, Klug WA, Steinwurz F, Rossini LG, Candelária PA (2009) Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2:221PubMedPubMedCentralCrossRefGoogle Scholar
  109. Wang MC, Zhang LY, Han W et al (2014) PRISMA – efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine 93:e326PubMedPubMedCentralCrossRefGoogle Scholar
  110. Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK (2016a) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 4:CD000543. doi: 10.1002/14651858.CD000543.pub4 PubMedGoogle Scholar
  111. Wang Y, Parker CE, Feagan BG, MacDonald JK (2016b) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 5:CD000544. Epub ahead of printGoogle Scholar
  112. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427–434PubMedCrossRefGoogle Scholar
  113. Yi-Zhen Z, Yong-Yu L (2014) Inflammatory bowel disease: pathogenesis. World J Gastroenterol 20(1):91–99CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Houston Methodist Hospital/Weill Cornell Medical CollegeHoustonUSA
  2. 2.UT Southwestern Medical CenterDallasUSA
  3. 3.University of Oklahoma Health Sciences CenterOklahoma CityUSA

Personalised recommendations